Welcome to our dedicated page for Glycomimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on Glycomimetics stock.
The GLYC news page on Stock Titan provides an archive of disclosures and announcements related to GlycoMimetics, Inc., a late clinical-stage biotechnology company that described itself as discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases. These news items trace the company’s scientific focus on small molecule glycomimetics and its corporate evolution leading to its merger with Crescent Biopharma, Inc.
Readers can review press releases detailing clinical trial milestones for uproleselan, an investigational, first-in-class E-selectin antagonist discovered and developed by GlycoMimetics. News coverage includes topline and comprehensive results from a pivotal Phase 3 study in relapsed/refractory AML, updates on an adaptive Phase 2/3 study in newly diagnosed AML conducted by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, and announcements of data presentations at major medical meetings such as the American Society of Hematology (ASH) Annual Meeting.
The archive also includes corporate updates, such as the initiation of a strategic review and corporate restructuring plan, discussions of potential business development opportunities for uproleselan and GMI-1687, and workforce reductions described as part of extending the company’s cash runway. Later news items document the acquisition agreement with Crescent Biopharma, the planned operation of the combined company under the Crescent Biopharma, Inc. name, and stockholder approval of the merger and related reverse stock split.
Because GlycoMimetics has completed a business combination and changed its name to Crescent Biopharma, Inc., the GLYC news feed serves primarily as a historical record. Investors and researchers can use this page to follow the sequence of clinical, regulatory, and strategic announcements that shaped the legacy GlycoMimetics business prior to its transition to trading under the CBIO symbol.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced the completion of patient enrollment in its pivotal Phase 3 trial evaluating uproleselan in combination with standard chemotherapy for relapsed/refractory acute myeloid leukemia (AML). A total of 388 patients were enrolled across 70 sites in nine countries, aiming for a primary endpoint of overall survival. Topline results are expected after 2022. Uproleselan, designed to target E-selectin, has received Breakthrough Therapy Designation from the U.S. FDA for adult AML patients, potentially marking a shift in treatment paradigms.
GlycoMimetics (NASDAQ: GLYC) announced acceptance of two abstracts for poster presentations at the 63rd American Society of Hematology Annual Meeting, set for December 11-14, 2021. The presentations will detail preclinical studies of GMI-1359, a dual antagonist targeting CXCR4 and E-selectin. Data suggest GMI-1359 may enhance treatment efficacy for AML and potentially improve survival rates in patients, particularly those with FLT-3 ITD mutations. The drug has received both Orphan Drug and Rare Pediatric Designations for osteosarcoma.
GlycoMimetics, Inc. (Nasdaq: GLYC) announces that CEO Harout Semerjian will present at two upcoming healthcare conferences. The Stifel 2021 Virtual Healthcare Conference will take place on November 15, with GlycoMimetics presenting at 3:20 p.m. ET. The Jefferies London Healthcare Conference is scheduled for November 17, with the presentation at 11:20 AM GMT (6:20 AM ET). GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, advancing its drug pipeline located in Rockville, MD.
GlycoMimetics (Nasdaq: GLYC) reported significant advancements in their investigational drug candidate, uproleselan. The Phase 3 trial for relapsed/refractory AML is nearing completion of enrollment, with top-line results expected post-2022. Recent data published in BLOOD showed a 69% MRD negativity rate among trial participants, enhancing uproleselan's profile. Financially, cash reserves stood at $101.9 million as of September 30, 2021, down from $137 million at year-end 2020, with R&D expenses increasing to $13.3 million due to ongoing clinical trials.
GlycoMimetics, Inc. (Nasdaq: GLYC) will hold a conference call on Tuesday, November 2, 2021, at 8:30 a.m. ET to discuss its third quarter financial results. Domestic participants can join at (844) 413-7154, while international callers can dial (216) 562-0466. A replay of the webcast will be available for 30 days on the company's website, and a phone replay will be accessible for 24 hours post-call. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, utilizing its unique chemistry platform.
GlycoMimetics announced promising results from a Phase 1/2 study of uproleselan, demonstrating a 69% MRD negative rate in relapsed/refractory AML patients. Published on September 16, 2021, in the journal BLOOD, the study indicates that uproleselan can enhance the efficacy of chemotherapy without increasing toxicity. The results support the ongoing Phase 3 trial, with hopes to establish uproleselan as the new standard of care for this patient population. Key findings include a median overall survival of 8.8 months for relapsed/refractory patients treated with the drug.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will present at the H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The presentation will be accessible on the company's website starting September 13 at 7:00 a.m. EDT for 30 days. GlycoMimetics, a clinical-stage biotechnology firm, focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, with its lead drug candidate, uproleselan, currently in a Phase 3 trial for relapsed/refractory acute myeloid leukemia.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced the grant of non-qualified stock options for 1,647,600 shares to Harout Semerjian, the new President and CEO, on August 3, 2021. The options were part of his inducement to accept the position, with a base exercise price of $2.03 per share. Vesting includes standard timelines and is contingent upon FDA approval of the candidate uproleselan for relapsed/refractory acute myeloid leukemia. GlycoMimetics is focused on developing therapies leveraging glycobiology for serious diseases.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported a cash position of $118.9 million as of June 30, 2021. The company is advancing six clinical trials for its lead candidate, uproleselan, including three registration trials, with anticipated data flow beginning in 2022. Enrollment is expected to conclude by year-end 2021 in pivotal studies addressing AML. Additionally, the announcement of a new CEO, Harout Semerjian, aims to reinforce the company's strategic direction and pipeline development as it progresses towards commercialization.
GlycoMimetics, Inc. (Nasdaq: GLYC) appointed Harout Semerjian as CEO effective August 6, 2021, succeeding founding CEO Rachel King. Semerjian, with extensive oncology commercialization experience, will guide the firm through registrational trials for its lead candidate, uproleselan, in AML. King, who has led the company for 18 years, will remain as a board member and advisor. Semerjian’s experience includes leadership roles at Novartis and Ipsen, and he emphasizes the potential of uproleselan, which holds Breakthrough Therapy Designation from the FDA and Chinese regulators.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
